Insight Molecular Diagnostics Inc. (IMDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Insight Molecular Diagnostics Inc. (IMDX) has a cash flow conversion efficiency ratio of 0.715x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.64 Million) by net assets ($-10.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Insight Molecular Diagnostics Inc. net asset quality index to measure how much of total assets are equity-financed.
Insight Molecular Diagnostics Inc. - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Insight Molecular Diagnostics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Insight Molecular Diagnostics Inc. (IMDX) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Insight Molecular Diagnostics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Insight Molecular Diagnostics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cartesian Growth Corporation II Class A Ordinary Shares
NASDAQ:RENE
|
-0.007x |
|
Readytech Holdings Ltd
AU:RDY
|
0.039x |
|
Teladan Setia Group Bhd
KLSE:0230
|
0.033x |
|
EDAP TMS SA
NASDAQ:EDAP
|
-0.294x |
|
Jeld-Wen Holding Inc
NYSE:JELD
|
0.098x |
|
Auna S.A.
NYSE:AUNA
|
0.052x |
|
Sanurhasta Mitra PT
JK:MINA
|
0.002x |
|
Vieworks Co. Ltd
KQ:100120
|
0.043x |
Annual Cash Flow Conversion Efficiency for Insight Molecular Diagnostics Inc. (2013–2025)
The table below shows the annual cash flow conversion efficiency of Insight Molecular Diagnostics Inc. from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see IMDX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-31.46 Million | $-22.18 Million | 0.705x | -58.22% |
| 2024-12-31 | $-12.27 Million | $-20.71 Million | 1.688x | +248.08% |
| 2023-12-31 | $20.47 Million | $-23.32 Million | -1.140x | +0.98% |
| 2022-12-31 | $39.59 Million | $-45.57 Million | -1.151x | -108.83% |
| 2021-12-31 | $65.22 Million | $-35.94 Million | -0.551x | +28.97% |
| 2020-12-31 | $33.48 Million | $-25.98 Million | -0.776x | -21.37% |
| 2019-12-31 | $30.84 Million | $-19.71 Million | -0.639x | +81.21% |
| 2018-12-31 | $3.42 Million | $-11.65 Million | -3.403x | -11.95% |
| 2017-12-31 | $4.40 Million | $-13.38 Million | -3.040x | -298.57% |
| 2016-12-31 | $9.86 Million | $-7.52 Million | -0.763x | -87.88% |
| 2015-12-31 | $10.42 Million | $-4.23 Million | -0.406x | -137.46% |
| 2014-12-31 | $-1.07 Million | $-1.16 Million | 1.084x | +651.82% |
| 2013-12-31 | $3.62 Million | $-710.00K | -0.196x | -- |
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expre… Read more